Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melapuldencel-T
- Development stage
- Discontinued
- Lead developer
- Lisata Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Melapuldencel-T is an autologous cellular immunotherapy developed for the treatment of metastatic melanoma. The therapy consists of a patient's own dendritic cells that have been loaded with antigens from irradiated autologous melanoma-initiating (stem) cells. This personalized approach aims to train the patient's immune system to recognize and destroy cancer stem cells, which are believed to be responsible for tumor recurrence and metastasis. The product is typically administered alongside granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance the maturation and activity of the dendritic cells. While it showed promise in Phase 2 trials and entered a Phase 3 trial (the "Intus" study), development was suspended by the developer (then Caladrius Biosciences) due to strategic and financial considerations.
- Other names
- Autologous Dendritic Cell-Tumor Cell ImmunotherapyDC-TC
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)Patient-specific melanoma-associated antigens and melanoma stem cell antigens
Beyond the preview
Go deeper on melapuldencel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melapuldencel-T.